Pulmonary arterial hypertension (PAH) is a rare, progressive disorder impacting small pulmonary arteries, leading to increased vascular resistance and heart failure. The latest report forecasts ...

The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK ...

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...

Lynn Hopkins of Ohio is happy she went with her gut and continued to explore her health issues, because it eventually led her ...

UBS analyst Ashwani Verma maintained a Buy rating on United Therapeutics (NASDAQ:UTHR) on June 30 but adjusted the price ...

Panelists discuss how cost-effectiveness analyses of newer therapies like sotatercept show substantial benefits in reducing clinical worsening events and potentially decreasing downstream costs ...

Cleveland Clinic Abu Dhabi has made history by performing the Gulf region’s first-ever robotic lung transplant, making it one ...